Successful Use of Ranolazine in SCN5A p.R222Q–Related Multifocal Ectopic Purkinje‐Related Premature Contractions
- 20 May 2026
- journal article
- case report
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (7) , 1618-1622
Abstract
Introduction: Gain‐of‐function variants in SCN5A may cause multifocal ectopic Purkinje‐related premature contractions (MEPPC), with a high premature ventricular contraction burden that may lead to PVC‐induced cardiomyopathy. Pharmacological therapy is usually required, as catheter ablation is ineffective because of the multifocal origin of the ectopy. Methods and Results: We report two siblings with the pathogenic SCN5A p.Arg222Gln variant. In both, ranolazine markedly suppressed ventricular ectopy, improved or preserved left ventricular function, and enabled amiodarone withdrawal. Conclusion: Ranolazine may represent a useful mechanism‐guided option for SCN5A‐related MEPPC.Keywords
This publication has 11 references indexed in Scilit:
- 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2022
- SCN5A overlap syndromes: An open-minded approachHeart Rhythm, 2022
- Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 PatientsFrontiers in Pharmacology, 2020
- Ranolazine: A Contemporary ReviewJournal of the American Heart Association, 2016
- Escape capture bigeminy: Phenotypic marker of cardiac sodium channel voltage sensor mutation R222QHeart Rhythm, 2012
- Multifocal Ectopic Purkinje-Related Premature ContractionsJACC, 2012
- Ranolazine Shortens Repolarization in Patients with Sustained Inward Sodium Current Due to Type‐3 Long‐QT SyndromeJournal of Cardiovascular Electrophysiology, 2008
- Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazineHeart, 2006
- Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more?British Journal of Pharmacology, 2006
- Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic PropertiesCirculation, 2004